stockrow
Friday 6 November 2026
Export ERAS’s income statement to Excel — free account
Erasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
14.34
1.07
+8.06%
Follow ERAS
Alert me
Erasca, Inc. (ERAS) Total debt
Erasca, Inc.'s total debt at the end of fiscal 2022 was $55.1M, up 193.2% from $18.8M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $56.8M. Erasca, Inc. ranks 125th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $55.1M | 193.21% |
| FY2021 | $18.8M | 529.30% |
| FY2020 | $3.0M | (19.06%) |
| FY2019 | $3.7M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $56.8M | (1.53%) |
| Jun 2023 | $57.6M | (0.72%) |
| Mar 2023 | $58.1M | 5.37% |
| Dec 2022 | $55.1M | 1.17% |
| 7 more quarters | Free account |
Total debt against peers
| Company | Total debt |
|---|---|
| TVTX Travere Therapeutics, Inc. compare | $603.5M |
| CRSP CRISPR Therapeutics AG compare | $586.9M |
| COGT Cogent Biosciences, Inc. compare | $223.5M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | $156.4M |
| ERAS Erasca, Inc. | $56.8M |
| DFTX Definium Therapeutics, Inc. compare | $36.5M |
| EWTX Edgewise Therapeutics, Inc. compare | $5.6M |
| DNTH Dianthus Therapeutics, Inc. compare | $670.0K |
| MANE Veradermics Incorporated compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt